Product Center
World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09
- Views:
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan.
World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines
(Summary description)From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-07-09 14:04
- Views:
From July 5 to 7, the 2024 World Influenza Conference, co-sponsored by the Chinese Preventive Medicine Association, the Asia-Pacific Influenza Control Alliance, the Chinese Center for Disease Control and Prevention, and the Chinese Academy of Medical Sciences, was held in Hainan.
Nearly 100 influenza prevention and control experts and public health professionals from five continents gathered in Boao to exchange and share the world's most advanced influenza prevention and control experience around the theme of "Comprehensive Prevention and Control from Influenza to Respiratory Infectious Diseases", and called for joint efforts in global influenza prevention and control.
As one of the supporters of this conference, Ab&B Bio attended the conference with its product, the first domestically-developed quadrivalent influenza virus subunit vaccine "Huier Kangxin", and invited a number of industry experts to discuss the recent influenza epidemic situation and the research progress of new influenza vaccines, providing "subunit" strength for China's influenza prevention and control.
"Huier Kangxin" has the unique qualities of "one high, two few, and three effective" (high purity of effective antigens, few adverse reactions, and efficient protection), and brings special technologies around health and safety, providing more possibilities for low pain and safe vaccination.
After 9 years of deep cultivation in subunit vaccines, based on long-term technological accumulation and continuous innovation, Zhonghui Bio is committed to creating healthy vaccine solutions that meet needs, making safety and health a reality.
At the academic seminar held on the afternoon of July 5, experts from the fields of influenza disease monitoring, prevention and control, and clinical trials introduced the recent influenza epidemic situation, the clinical research progress and application of the domestically produced new quadrivalent subunit influenza vaccine, and demonstrated the process characteristics, immunogenicity and safety advantages of subunit influenza vaccines to the experts and scholars attending the meeting. The quadrivalent subunit influenza vaccine Huier Kangxin will provide a new generation of influenza vaccine "weapons" for influenza prevention and control in the 2024-2025 influenza season, helping China's influenza prevention and control.
At the meeting held from July 6 to 7, experts mentioned that the current global influenza prevention and control work still faces many challenges: global climate change, urbanization, intensive animal husbandry, cross-border trade facilitation, etc., have superimposed the driving factors of influenza epidemics; the mutation and recombination of influenza viruses continue worldwide, and human infection with animal-derived influenza epidemics also occur from time to time, and the risk of influenza pandemics always exists. Ab&B Bio focuses on the unmet needs in influenza prevention and control, and has deployed multiple subunit influenza vaccine products for adults, children, and the elderly. At the same time, Ab&B Bio actively deploys overseas registrations and will contribute more Chinese strength to global influenza prevention and control.
Biotechnology is subverting the future of vaccines in an unprecedented way. As an innovation-leading company, Zhonghui Bio has been deeply engaged in subunit vaccines for many years, continuously investing in research and development, accelerating product progress and the development of key technologies, and exploring the future paradigm of vaccine innovation and development.
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
